Shackelford, David B <br/><br/>
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.  [electronic resource] 

 -  Cancer cell  Feb 2013 
 - 143-58 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1878-3686 
<br/><br/><label>Standard No.: </label>10.1016/j.ccr.2012.12.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AMP-Activated Protein Kinases--genetics<br/>Animals<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Proliferation--drug effects<br/>Cells, Cultured<br/>Eukaryotic Initiation Factor-2--genetics<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Lung Neoplasms--drug therapy<br/>Mice<br/>Mice, Knockout<br/>Mitochondria--drug effects<br/>Mutation--genetics<br/>Phenformin--therapeutic use<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins p21(ras)--physiology<br/>RNA, Messenger--genetics<br/>Real-Time Polymerase Chain Reaction<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Tumor Suppressor Protein p53--physiology